In vitro activity of tigecycline against multidrug resistant A. baumannii isolates
Abstract number: 1733_1186
Yilmaz Bozkurt G., Memikoglu K.O., Kutlu H., Azap A., Çokça F.
Objectives:Acinetobacter baumannii is one of the important pathogens of the hospital infections. The evaluation of the in vitro activity of tigecycline in comparison to imipenem, meropenem, tazobactam-piperacillin and cefoperazone-sulbactam against Acinetobacter baumannii strains.
Methods: A total of 100 Acinetobacter baumannii clinical strains isolated during the period of September 2005September 2006 were tested. The isolates originated from a wide variety of clinical specimens including tracheal aspirate (30), sputum (6), blood (17), central venous catheter (4), abscess-wound swabs (30), abdominal drain fluid (4), cerebrospinal fluid (1), pleural fluid (1), bile (1), urine (5). Sixty percent of these isolates was from clinics of surgery where as 40% was from internal medicine clinics. Their Minimum Inhibitory Concentration (MICs) were determined by using E-Test according to CLSI (Clinical Laboratories Standarts Institute) guidelines.
Results: Overall MIC90 to tigecycline, imipenem, meropenem, tazobactam-piperacillin and cefoperazone-sulbactam were 6 mg/L, >32 mg/L, >32 mg/L, >256 mg/L, >256 mg/L, respectively, whereas MIC50 were 2 mg/L, >32 mg/L, >32 mg/L, >256 mg/L, 32 mg/L, respectively.
Conclusion: In general, tigecycline showed better in vitro activity than imipenem, meropenem, tazobactam-piperacillin and cefoperazone-sulbactam against Acinetobacter baumanii strains. The results show that tigecycline should be considered as a possible alternative for the treatment of Acinetobacter baumannii infections.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|